tert-butyl 4-((4-bromobenzamido)methyl)piperidine-1-carboxylate | 1008505-58-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: tert-butyl 4-((4-bromobenzamido)methyl)piperidine-1-carboxylate
• 英文别名: Tert-butyl 4-[[(4-bromobenzoyl)amino]methyl]piperidine-1-carboxylate
• CAS: 1008505-58-5
• 化学式: C₁₈H₂₅BrN₂O₃
• 分子量: 397.312
• InChiKey: FETGGQLNSSYSHE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  24
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  58.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-((4-bromobenzamido)methyl)piperidine-1-carboxylate 在 盐酸 作用下， 以 乙酸乙酯 为溶剂， 生成
  参考文献：
  名称：

  Targeting Acidic Mammalian chitinase Is Effective in Animal Model of Asthma

  摘要：

  This article highlights our work toward the identification of a potent, selective, and efficacious acidic mammalian chitinase (AMCase) inhibitor. Rational-design, guided by X-ray analysis of several inhibitors bound to human chitotriosidase (hCHIT1), led to the identification of compound 7f as a highly potent AMCase inhibitor (IC50 values of 14 and 19 nM against human and mouse enzyme, respectively) and selective (>150X against mCHIT1) with very good PK properties. This compound dosed once daily at 30 mg/kg po showed significant anti-inflammatory efficacy in HDM-induced allergic airway inflammation in mice, reducing inflammatory cell influx in the BALF and total IgE concentration in plasma, which correlated with decrease of chitinolytic activity. Therapeutic efficacy Of compound 7f in the clinically relevant aeroallergen-induced acute asthma model in mice provides a rationale for developing AMCase inhibitor for the treatment of asthma.

  DOI：

  10.1021/acs.jmedchem.7b01051
• 作为产物：
  描述：

  4-溴苯甲酸 、 1-叔丁氧羰基-4-氨甲基哌啶 在 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 以94%的产率得到tert-butyl 4-((4-bromobenzamido)methyl)piperidine-1-carboxylate
  参考文献：
  名称：

  Targeting Acidic Mammalian chitinase Is Effective in Animal Model of Asthma

  摘要：

  This article highlights our work toward the identification of a potent, selective, and efficacious acidic mammalian chitinase (AMCase) inhibitor. Rational-design, guided by X-ray analysis of several inhibitors bound to human chitotriosidase (hCHIT1), led to the identification of compound 7f as a highly potent AMCase inhibitor (IC50 values of 14 and 19 nM against human and mouse enzyme, respectively) and selective (>150X against mCHIT1) with very good PK properties. This compound dosed once daily at 30 mg/kg po showed significant anti-inflammatory efficacy in HDM-induced allergic airway inflammation in mice, reducing inflammatory cell influx in the BALF and total IgE concentration in plasma, which correlated with decrease of chitinolytic activity. Therapeutic efficacy Of compound 7f in the clinically relevant aeroallergen-induced acute asthma model in mice provides a rationale for developing AMCase inhibitor for the treatment of asthma.

  DOI：

  10.1021/acs.jmedchem.7b01051

文献信息

• [EN] SUBSTITUTED AMINO TRIAZOLES, AND METHODS USING SAME<br/>[FR] TRIAZOLES AMINO-SUBSTITUÉS ET PROCÉDÉS D'UTILISATION
  申请人：INST DRUG DELIVERY

  公开号：WO2015095701A1

  公开（公告）日：2015-06-25

  Disclosed are novel substituted amino triazoles of Formula (I), and pharmaceutically acceptable salts thereof. The compounds of Formula (I) are inhibitors of Acidic mammalian chitinase (AMCase) and are useful, in a non-limiting example, for treating asthma. Also provided are pharmaceutical compositions containing at least one compound of the present invention, or a pharmaceutically acceptable salt, hydrate or solvate thereof, and at least one pharmaceutically acceptable carrier, solvent, adjuvant or diluent, and methods of using such compounds and/or compositions to treat asthma and/or to monitor asthma treatment.

  公开了化合物的新型替代氨基三唑的结构，其化学式为（I），以及其药学上可接受的盐。化合物的化学式（I）是酸性哺乳动物几丁质酶（AMCase）的抑制剂，并且在非限制性示例中用于治疗哮喘。还提供了含有本发明至少一种化合物或其药学上可接受的盐、水合物或溶剂化合物的药物组合物，以及至少一种药学上可接受的载体、溶剂、辅料或稀释剂，并使用这些化合物和/或组合物来治疗哮喘和/或监测哮喘治疗的方法。
• Discovery of novel tetrahydrobenzo[b]thiophene-3-carbonitriles as histone deacetylase inhibitors
  作者：Piyush Gediya、Vivek K. Vyas、Vincenzo Carafa、Nikum Sitwala、Laura Della Torre、Angelita Poziello、Takashi Kurohara、Takayoshi Suzuki、Vinod Sanna、Varalakshmi Raguraman、K. Suthindhiran、Debarpan Ghosh、Dhiraj Bhatia、Lucia Altucci、Manjunath D. Ghate

  DOI：10.1016/j.bioorg.2021.104801

  日期：2021.5

  isoform-selective histone deacetylase (HDAC) inhibitor is a challenging task because of the sequence homology among HDAC enzymes. In the present work, novel tetrahydro benzo[b]thiophene-3-carbonitrile based benzamides were designed, synthesized, and evaluated as HDAC inhibitors. Pharmacophore modeling was our main design strategy, and two novel series of tetrahydro benzo[b]thiophene-3-carbonitrile derivatives with

  由于 HDAC 酶之间的序列同源性，异构体选择性组蛋白脱乙酰酶 (HDAC) 抑制剂的发现和开发是一项具有挑战性的任务。在目前的工作中，新型四氢苯并[ b ]噻吩-3-甲腈基苯甲酰胺被设计、合成并评估为HDAC抑制剂。药效团建模是我们的主要设计策略，两个新系列的四氢苯并[ b ]噻吩-3-甲腈衍生物与哌啶接头（系列 1）和哌嗪接头（系列 2）被鉴定为 HDAC 抑制剂。在所有合成的化合物中，9h带有 4-（氨基甲基）哌啶接头和14n哌嗪接头分别对人 HDAC1 和 HDAC6 表现出良好的活性。这两种化合物还对几种人类癌细胞系表现出良好的抗增殖活性。这两种化合物（9h和14n）还在 U937 和 MDA-MB-231 癌细胞中诱导细胞周期停滞和细胞凋亡。总的来说，这项研究首次发现了有效的异构体选择性 HDAC 抑制剂，它使用环状接头代替脂肪链和芳香环系统，这在已知的 HDAC 抑制剂中已有报道。
• SUBSTITUTED AMINO TRIAZOLES, AND METHODS USING SAME
  申请人：The Institute For Drug Delivery

  公开号：EP3082805A1

  公开（公告）日：2016-10-26